Centivax is a biotechnology startup focused on developing broad-spectrum vaccines, particularly targeting influenza. The company is currently in the pre-clinical development phase, testing its influenza vaccine in ferrets and pigs. This innovative approach has garnered significant attention, including an award from the Gates Foundation's Grand Challenge to End the Pandemic Threat. Additionally, Centivax was featured in the Netflix docuseries "Pandemic: How to Prevent an Outbreak," highlighting its potential impact on global health.

Centivax primarily serves the healthcare sector, including pharmaceutical companies, healthcare providers, and potentially government health agencies. The market it operates in is the global vaccine market, which is crucial for preventing infectious diseases and is valued at billions of dollars annually.

The business model of Centivax revolves around research and development (R&D) of vaccines, securing funding through grants and partnerships, and eventually licensing their vaccine technology to larger pharmaceutical companies. This model allows them to focus on innovation while leveraging the distribution and marketing capabilities of established players in the pharmaceutical industry.

Centivax makes money through a combination of grant funding, such as the one received from the Gates Foundation, and future licensing deals. Once their vaccines are proven effective and safe through clinical trials, they can license the technology to pharmaceutical companies, earning revenue through upfront payments, milestone payments, and royalties on sales.

In summary, Centivax is a promising biotech startup with a focus on developing broad-spectrum vaccines to combat influenza and other infectious diseases. Their innovative approach and strategic partnerships position them well in the competitive global vaccine market.

Keywords: Biotechnology, Vaccines, Influenza, Pre-clinical Development, Gates Foundation, Pandemic Prevention, Healthcare, R&D, Licensing, Pharmaceutical.